Thermo Fisher Precision Oncology Seminar

Accelerating oncology translational research with targeted next generation sequencing

North Carolina Biotechnology Center | November 02, 2017 - November 02, 2017 | 09:30 - 13:00 Add to Calendar
Stay Informed Register Now

About This Event

Advances in targeted next-generation sequencing have been instrumental in quickening the pace of discovery in oncology and translational research.

In fact, targeted next generation sequencing allows for the ability to analyze only the genes of interest in a rapid, cost-effective manner and thus has the potential to transform the strategies and workflow of oncology research.

Join Q2 Solutions at the Thermo Fisher Precision Oncology Seminar, where Stephanie Hastings, Q2 Solutions, will be leading a discussion on Targeted Genomic Profiling using Ion Oncomine Comprehensive Assays.

Address: 15 T.W. Alexander Drive, Research Triangle Park, NC 27709
Room: Glaxo Galleria Room

We look forward to seeing you there!


Stephanie B. Hastings, Ph.D.
Staff Scientist II, Assay Development, Translational Genomics

Stephanie B. Hastings, Ph.D., is a Staff Scientist II in Assay Development, Translational Genomics at Q2 Solutions | EA Genomics. In this role, she is responsible for the development and validation of genomic assays to support research and clinical programs. Stephanie is currently leading development efforts surrounding liquid biopsy applications as well as panel-based tumor mutational burden (TMB) next-generation sequencing (NGS) analyses. 

Stephanie has more than 10 years of experience across diverse disciplines including: clinical molecular diagnostics, animal health vaccine development, genetic engineering and protein biochemistry.

Stephanie earned a Bachelors degree in Microbiology from North Carolina State University, followed by a Ph.D. in Biochemistry and Molecular Biology at the University of Georgia

Minimal Residual Disease Detection: Key Considerations for Clinical Development in Oncology

Current MRD detection landscape, key considerations for each approach, and current advancements that will contribute to further improvements in MRD detection

Genomic Based Solutions for Your Immuno-oncology Drug Development Needs

Genomics-based biomarker approach

Genomic Assays for Clinical Development

Identifying the right approach from a wealth of potential options

New Opportunities for Immuno-oncology Clinical Development Programs through T cell/B cell Repertoire Profiling

Immune repertoire profiling provides better outcomes for immuno-oncology development programs

Read More